These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 32086819

  • 1. A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen allo-immunized patients.
    Vo P, Purev E, West KA, McDuffee E, Worthy T, Cook L, Hawks G, Wells B, Shalabi R, Flegel WA, Adams SD, Reger R, Aue G, Tian X, Childs R.
    Br J Haematol; 2020 May; 189(3):551-558. PubMed ID: 32086819
    [Abstract] [Full Text] [Related]

  • 2. Determination in vivo viability of a transfused platelet product by corrected count increment and percentage platelet response.
    Thuku NW, Shikuku K, Mbugua A.
    Pan Afr Med J; 2017 May; 27():226. PubMed ID: 28979628
    [Abstract] [Full Text] [Related]

  • 3. [Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness].
    Basire A, Picard C.
    Transfus Clin Biol; 2014 Nov; 21(4-5):193-206. PubMed ID: 25277423
    [Abstract] [Full Text] [Related]

  • 4. Platelet transfusion refractoriness and anti-HLA immunization.
    Blandin L, Dougé A, Fayard A, Bay JO, Berlie G, Pereira B, Lemal R, Rouzaire P.
    Transfusion; 2021 Jun; 61(6):1700-1704. PubMed ID: 33709433
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Complement as an Immune Barrier in Platelet Transfusion Refractoriness.
    Meinke S, Karlström C, Höglund P.
    Transfus Med Rev; 2019 Oct; 33(4):231-235. PubMed ID: 31679761
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Human Leukocyte Antigen Class I Antibodies and Response to Platelet Transfusion in Patients Undergoing Liver Transplantation.
    Wong M, Narra R, Selim M, Zimmerman MA, Kim J, Padmanabhan A, Hong JC.
    J Surg Res; 2020 Nov; 255():99-105. PubMed ID: 32543385
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Human Leukocyte Antigen Alloimmunization and Alloimmune Platelet Refractoriness.
    Saris A, Pavenski K.
    Transfus Med Rev; 2020 Oct; 34(4):250-257. PubMed ID: 33127210
    [Abstract] [Full Text] [Related]

  • 12. Platelet transfusion refractoriness associated with HPA-1a (Pl(A1)) alloantibody without coexistent HLA antibodies successfully treated with antigen-negative platelet transfusions.
    Pappalardo PA, Secord AR, Quitevis P, Haimowitz MD, Goldfinger D.
    Transfusion; 2001 Aug; 41(8):984-7. PubMed ID: 11493728
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Use of Human Leukocyte Antigen (HLA)-Incompatible Platelet Units in HLA Platelet-Refractory Patients With Limited Number of or Low-Level HLA Donor-Specific Antibodies Results in Permissive Transfusions.
    Sullivan JC, Peña JR.
    Arch Pathol Lab Med; 2022 Oct 01; 146(10):1243-1251. PubMed ID: 35171984
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. HLA-Mediated Platelet Refractoriness.
    Schmidt AE, Refaai MA, Coppage M.
    Am J Clin Pathol; 2019 Mar 01; 151(4):353-363. PubMed ID: 30285067
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.